Navigation Links
Dominion Diagnostics -- The Only Specialty Urine Drug Monitoring Laboratory to Offer Quantitative Detection of Tapentadol (Nucynta(TM)) by LC/MS/MS
Date:9/14/2009

NORTH KINGSTOWN, R.I., Sept. 14 /PRNewswire/ -- Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.

Dominion's new assay by LC/MS/MS can detect and identify the primary drug tapentadol. Tapentadol is extensively metabolized in humans. In clinical studies 97% of the administered dose was metabolized, with 70% of the dose excreted in the urine in the conjugated form (55% as tapentadol-O-glucuronide and 15% and tapentadol-O-sulfate). Tapentadol excretion is almost exclusively renal. In a clinical study, it was shown that greater than 95% of a single dose of tapentadol was excreted in the urine within 24 hours of oral administration(1).

"This is a noteworthy achievement for our Research & Development (R&D) and Laboratory Teams," stated Chief Operating Officer Stephen Jordan. "Dominion has invested considerable time and resources in developing this new tapentadol assay. Providing assays for new pain medications allows us to better support our clients' need for relevant and accurate technologies when relying on urine drug monitoring to support patient adherence."

Dominion's quantitative tapentadol assay, one of the first presented to the industry, is now available to all clients across the country. This new development comes as part of Dominion's continued commitment to unparalleled laboratory excellence. Dominion continues to lead the industry in its quest for accurate, clinically relevant science for use in appropriately monitoring chronic pain patients. Dominion's R&D team actively works with leading assay manufacturers and pharmaceutical companies to develop accurate, specific tests that meet current and future needs of the growing pain management industry.

"Our LC/MS/MS assay for tapentadol is highly sensitive and offers clinicians an accurate means of detecting tapentadol in patients that are prescribed the drug, patients that may be diverting their medications, or in other cases where a patient may have been provided the drug from other sources," Dominion's Director of Research & Development Matthew Woodcock, Ph.D. commented. "At Dominion, we recognize the important clinical implications of urine drug monitoring, and we pride ourselves on offering scientifically accurate solutions to support every clinical scenario."

Source:

(1) Terlinden R et al., Eur J Drug Metab Pharmacokinet (2007); Jul-Sep 32(3): 163-169.

Nucynta(TM) is a registered trademark of Ortho-McNeil(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

ABOUT DOMINION DIAGNOSTICS

Dominion Diagnostics is a premier provider of comprehensive clinical quantitative urine drug testing, medication monitoring and support services nationwide. For over 13 years, Dominion has provided services to thousands of clients in a variety of medical specialties, including Pain Medicine, Primary Care, Addiction Treatment, Behavioral Health, Psychiatry and Hospital Systems. Dominion is supported by a world-class team that shares a commitment to clinical and operational excellence. For more information about Dominion, please visit www.dominiondiagnostics.com.

    Contact:
    Julie Lenahan
    Director of Marketing
    Dominion Diagnostics
    (401) 667-0876
    jlenahan@dominiondiagnostics.com


'/>"/>
SOURCE Dominion Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dominion Diagnostics to Host Open House Reception in New Vermont Laboratory Facility
2. Dominion Helps Communities by Donating $1 Million to Health Clinics
3. Capital BlueCross Acquires Dominion Dental
4. Dominion Diagnostics Announces Launch of Comprehensive New Company Website
5. Dominion Diagnostics Supports Rhode Islands Toys for Tots Initiative at Its 2007 Holiday Celebration
6. Quest Diagnostics To Speak at the Bank of America Merrill Lynch Global Healthcare Conference
7. Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index
8. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
9. Frost & Sullivan: Malaysia Diagnostics and Devices Industry Outlook 2009
10. Quest Diagnostics Declares Quarterly Cash Dividend
11. eCardio Diagnostics Expands Corporate Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line ... in Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than ... by government agencies, including NASA. , In 2012, NASA strategically set up 17 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks ... Amica Insurance is sharing tips to make sure your family and vehicle are ... National Safety Council, there may be 439 deaths and an additional 50,500 serious injuries ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at ... daily practices, arts & crafts, discussions, and games all geared towards enhancing your ... have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite ... sales leadership and to further develop their rapidly expanding portfolio of customer and ... with a concentration in Marketing and an M.B.A. with concentration in management from ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
Breaking Medicine Technology: